Search Results

1,445 articles with title/keywords/abstract containing Development-status

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
modify search
Display per page 

Content loaded within last 14 days The product label for Optimark [gadoversetamide] is being modified

Source: Reactions, Volume 1, Number 1278, 2009-11-14 , pp. 4-4(1)

Publisher: Adis International

Forteo approved for new indication

Source: Reactions, Volume 1, Number 1263, 2009-08-01 , pp. 2-2(1)

Publisher: Adis International

Glucosamine [Glucomed] may be reimbursed in France

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 584, 2009-08-08 , pp. 10-10(1)

Publisher: Adis International

FDA is reviewing safety of omalizumab

Source: Reactions, Volume 1, Number 1262, 2009-07-25 , pp. 2-2(1)

Publisher: Adis International

Cetuximab gets the nod from NICE

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 580, 2009-06-13 , pp. 10-10(1)

Publisher: Adis International

Clevudine trial halted

Source: Reactions, Volume 1, Number 1250, 2009-05-02 , pp. 2-2(1)

Publisher: Adis International

An imbalance in overall survival has seen the SYMMETRY trial suspended.

Source: Reactions, Volume 1, Number 1243, 2009-03-14 , pp. 2-2(1)

Publisher: Adis International

Boceprevir proves promising for chronic hep C

Source: Inpharma, Volume 1, Number 1667, 2008-12-06 , pp. 9-9(1)

Publisher: Adis International

Prodarsan achieves positive results in phase I trial.

Source: Inpharma, Volume 1, Number 1667, 2008-12-06 , pp. 9-9(1)

Publisher: Adis International

modify search
Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A